AzTrials
AzTrials

Venoarteriolar ReflexNCT01280071

Adenosine Activity in Producing Venoarteriolar Reflexes

A study testing aminophylline in people with Venoarteriolar Reflex, run by Tel-Aviv Sourasky Medical Center.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Veno-arteriolar and veno- arteriolar-myogenic reflexes (VAR and VMR, respectively) are of the most important contributors to local vasoregulation. In a recent research we showed that VAR is affected in the affected lower limbs of CRPS (chronic regional pain syndrome) patients. Read more about this study

Who is it for?
Ages 18 to 50 years, men only
Conditions the study is for
Venoarteriolar Reflex
What is being tested?
aminophylline
Could I receive a placebo?
No, everyone receives an active treatment
How many people
Not given
Where
No sites listed yet
Study dates
Start not givento not given
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Men only
  • Adult

Who may be able to join

  • Males with no medical conditions, neither taking any chronic medications. (reflexes in female could be affected by the menstrual cycle, therefore we recruit only males)
  • Capable to read and sign an informed consent.
  • Normal blood count, liver function tests (albumin and coagulation profile, liver enzymes).
  • Normal EKG (will be performed in the beginning of the session and interpreted by a senior investigator).

Who cannot join

  • Any former medical condition affecting any system in the body (including cardiovascular).
  • History of allergy to any drug.
  • Smoker (smoking affects the aminophylline metabolism)
  • Inability to understand the experiment procedure and sign an informed consent.
  • Any history of trauma to the limbs.
  • History of neuropathic pain.
  • Systolic BP lower than 110 mm Hg
  • History of syncope or any heart arrhythmia

Trial locations and contacts

No sites are listed yet.

About this study

Veno-arteriolar and veno- arteriolar-myogenic reflexes (VAR and VMR, respectively) are of the most important contributors to local vasoregulation.

In a recent research we showed that VAR is affected in the affected lower limbs of CRPS (chronic regional pain syndrome) patients. {Dayan, 2008 1 /id} That is, local venous congestion (40 mmHg) results in a decreased blood flow in the affected, sick limb compared with its contralateral. The myogenic reflex, however, that is induced by lowering the leg 40 cm below heart level, which causes both venous and arteriolar congestion, was intact in the sick leg. We concluded that the pathophysiology of CRPS might involve a defect in the neural reflex between venous and arteriolar vessels. Arteriolar smooth muscle action, on the other hand, is intact and might compensate for the overwhelmed VAR.

Read more

Trying to explain the fact that VAR, but not VMR, was different between the affected and unaffected limbs, we raise the hypothesis that since VMR is a local vasoregulatory reflex composed of two components: the venous and myogenic, opposed to the VAR, the myogenoic component of the reflex might compensate for the inappropriate VAR. Many mechanisms that might affect vascular muscles may occur, one of them is related to adenosine.

Adenosine is considered a retaliatory autacoid, whose main function is to protect tissues against ischemia. It is a very potent vasodilator. Adenosine is also considered an important mediator of ischemic preconditioning, a phenomenon by which an initial brief period of ischemia protects the tissue from the damage produced by a subsequent more intense ischemic episode.

Adenosine has a pivotal role in local vasoregulation. In many researches it was shown that adenosine contributes to exercise hyperaemia in skeletal muscle. The 'adenosine hypothesis' states that blood flow is regulated by interstitial adenosine, released from cardiac or skeletal muscle fibers when there is a mismatch between O2 supply and O2 demand. When there is insufficient O2 to regenerate ATP, ADP and AMP accumulate leading to adenosine generation. By causing vasodilatation, adenosine helps to restore the O2 delivery, reversing the mismatch and allowing ATP to be regenerated.

Adenosine is a naturally occurring ligand of 4 subtypes of G-protein-coupled cell membrane receptors (A1, A2A, A2B, and A3) involved in cellular signaling. Dipyridamole produces coronary hyperemia by indirectly activating adenosine A2A receptors by inhibiting tissue uptake of adenosine and thereby increasing levels of endogenous adenosine.

Taking all these considerations into account we hypothesize that local vascular reflexes like VAR, and eventually VMR are mediated by adenosine. That is, adenosine produced at a constant rate in vascular bed contributing to constant blood flow under a wide range of local circumstances. A local increase in venous blood flow (as in lower limbs veins during prolonged standing) causes adenosine "wash out", which leads to local arterial vasoconstriction to reduce blood flow to the limb, which is, in fact, the purpose of VAR. if our hypothesis turns to be true, then when we will see exaggeration of the reflexes with adenosine blockade and vice versa, a decrease its abolishment with adenosine reuptake inhibition.

Being tested
aminophylline

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • aminophyllineDrug

Study groups in NCT01280071
Study groupRoleWhat they receive
dipyridamole, aminophyllineExperimentalNot described
Receives: Drug: aminophylline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To study whether increasing ore blocking adenosine activity changes arteriolar blood flow in the limb.

    The venoarteriolar reflex is the arteriolar vascocostriction response to venous congestion in the limb. The congestion is produced by lowering the limb below the heart level or increasing the soft tissue pressure (using a cuff)to above venous and below arteriolar pressure (to 40 mmHg). The vasoconstriction is assessed by comparing blood flow to the limb before and after the congestion. the units used for blood flow measurements are of flow: ml blood/100 ml tissue*sec^-1.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2011 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
IDs, dates and publications
ClinicalTrials.gov ID
NCT01280071
Sponsor's protocol ID
0431-10-TLV
Status last verified
Jan 2011
First submitted
3 Jan 2011
Last updated
20 Jan 2011
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing aminophylline in people with Venoarteriolar Reflex, run by Tel-Aviv Sourasky Medical Center.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Lior Dayan, MD (972504051014, liordayan.3105@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To study whether increasing ore blocking adenosine activity changes arteriolar blood flow in the limb.. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in